Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESELECT-0: Personalised Timing of IDS in Ovarian Cancer
NCT07022535Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- May 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The University of Hong Kong. Primary endpoints: Complete resection (CC0) rate up to 24 months and Sensitivity of KELIM in predicting CC0 up to 24 weeks. Started May 2024; status: recruiting.
02
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07022535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022535.